Buiten RA, Ploumen EH, Zocca P, et al. - Researchers analyzed all‐comer patients with severely calcified coronary lesions, to evaluate the 2‐year clinical performance of three drug‐eluting stents in this group of patients. Random allocation of 3,514 all‐comer patients to biodegradable polymer Synergy everolimus‐eluting stents (EES) or Orsiro sirolimus‐eluting stents, vs durable polymer Resolute Integrity zotarolimus‐eluting stents (ZES) was done in the BIO‐RESORT trial (a large‐scale, randomized clinical trial). Experts evaluated overall 783 patients (22.3%) with at least one severely calcified target lesion by performing this post hoc analysis. Findings revealed a lower 2‐year target vessel revascularization rate in relation to treatment with EES vs treatment with ZES in BIO‐RESORT participants having severely calcified target lesions.